BLLN
BillionToOne, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Overall ASP | $571 | Q1 2026 | — |
|
|
|||
| Total tests accessioned | 189,000 | Q1 2026 | — |
|
|
|||
| Total tests delivered | 188,000 | Q1 2026 | — |
|
|
|||
| ASP per test | $571 | Q1 2026 call | — |
| cash position | $537.5M | Q1 2026 call | — |
| COGS per test | $153 | Q1 2026 call | — |
| oncology volumes quarter-over-quarter growth | 25% | Q1 2026 call | — |
| prenatal volumes quarter-over-quarter growth | 10% | Q1 2026 call | — |
| test volume | 188,000 | Q1 2026 call | — |
| test volume growth | 44% | Q1 2026 call | — |
| Gross profit margin | 71% | Q4 FY2025 | — |
| Net cash flow, excluding the net proceeds received from the issuance of common stock in connecti non-GAAP | $12.5M | FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLLN
this stock
BillionToOne, Inc.
|
$5.83B | +56.4% | — | — | 5.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$195.86B | -9.0% | +0.4% | 29.0 | 1.4% |
|
DHR
Danaher Corp /De/
|
$138.71B | -12.7% | +8.5% | 37.8 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.46B | -16.7% | +10.4% | 41.5 | 2.5% |
|
NTRA
Natera, Inc.
|
$40.37B | +17.8% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLLN | +4.6% | +25.0% | +35.6% | +6.7% | +56.4% |
| SPY | +0.8% | +2.0% | +8.9% | +0.7% | +10.2% |
| vs SPY | +3.8% | +23.0% | +26.7% | +6.0% | +46.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.